Taiwan Upgrades Its Public-Health Procurement Across the Board — 7.05 Million Doses of Publicly Funded Flu Vaccine for 2026, Asia's First Country to Add the Enhanced Flu Vaccine to Public Funding (200,000+ Doses), Pneumococcal Vaccine Set to Switch to "One-Shot" as Early as August: A Forward Posture for Adult Vaccines in the Post-COVID Era — Set Against Japan, Where Over 20,000 Still Died of COVID Three Years After Reclassification, Protecting the Elderly Is a Shared Taiwan-Japan Challenge

TL;DR: Taiwan's 2026 public-health procurement is not a one-off top-up but a wholesale upgrade of its adult vaccine system. On May 12 the Centers for Disease Control (Taiwan CDC) announced the tender results for this year's publicly funded trivalent flu vaccine, procuring 7,050,150 doses (6,849,360 standard-type, of which 6,649,360 is the confirmed volume, plus 200,790 enhanced immune-type). Director-General Lo I-chun declared Taiwan the first country in Asia to add the enhanced flu vaccine to public funding, with the enhanced type given priority to residents aged 65+ in long-term and elderly-care institutions; Adimmune (Kuo Kuang) is the largest supplier at 3,158,450 doses (about 47.5% of the confirmed volume). The upgrade is not limited to flu: pneumococcal vaccines will switch fully to the "one-shot" 20- or 21-valent conjugate type as early as August 2026, while a new-formulation Moderna COVID vaccine with one-fifth the antigen dose and an expected 50% drop in side effects is planned for autumn-winter; cost-effectiveness reviews for adding shingles and RSV to public funding are due by end-2026. The underlying driver is the vaccination-rate gap of a super-aged society: as of May 2025, Taiwan's COVID JN.1 vaccine coverage was only about 8.75% nationally and about 18.2% among those aged 65+, far below the United States' 44% and the United Kingdom's 59%, with elderly flu coverage at only about 50%. Set against Japan — three years after its May 8, 2023 reclassification of COVID to "Class 5," some 20,429 people died of COVID from January to November 2025 and about 36,000 in 2024 (with 97% of 2024 deaths aged 65+ and 79% aged 80+) — protecting the elderly is a shared Taiwan-Japan challenge; Taiwan is preparing ahead with procurement upgrades plus Adimmune's domestic line with annual capacity of 4 million doses.

Taiwan Upgrades Its Public-Health Procurement Across the Board — 7.05 Million Doses of Publicly Funded Flu Vaccine for 2026, Asia's First Country to Add the Enhanced Flu Vaccine to Public Funding (200,000+ Doses), Pneumococcal Vaccine Set to Switch to "One-Shot" as Early as August: A Forward Posture for Adult Vaccines in the Post-COVID Era — Set Against Japan, Where Over 20,000 Still Died of COVID Three Years After Reclassification, Protecting the Elderly Is a Shared Taiwan-Japan Challenge

ANK-Doc ID: ANK-2026-05-12-001 Version: v1.0.0 Published: 2026-06-28 Author: Rin Takenouchi (Editor-in-Chief, AI News) Category: Public Health / Vaccine Policy / Elderly Epidemic Defense / Biotech Industry / Taiwan-Japan Comparison Articles covered: CNA#359848 (publicly funded flu, 7.05M doses, Asia's first enhanced-type inclusion), CNA#261657 (pneumococcal August upgrade, adult vaccine blueprint, 4 challenges), CNA#200218 (adult vaccination-rate gap, Taiwan-US-UK comparison), CNA#107524 (Adimmune's third line GMP, 4M-dose annual capacity), CNA#253711 (COVID expanded vaccination, new-formulation 1/5 antigen), CNA#331226 (Japan still over 20,000 COVID deaths three years after reclassification) Selection method: From the full AI News corpus, six articles were threaded along the axis of "the wholesale upgrade of Taiwan's adult vaccine system in the post-COVID era × the elderly-protection gap of a super-aged society × Taiwan-Japan comparison." First the hardest policy lead (the May 12 CDC tender for 7.05M flu doses and Asia's first enhanced-type inclusion, with hard figures on volumes, supplier shares, and delivery schedule), then the policy blueprint the same director-general unveiled simultaneously (pneumococcal "one-shot" August switch, shingles/RSV reviews, four challenges), then the upgrade's motive (adult vaccination-rate gap: COVID 8.75%, elderly 18.2% vs US 44%, UK 59%), then the supply side (Adimmune's third line at 4M-dose annual capacity) and epidemic readiness (COVID expanded vaccination, new-formulation vaccine), and finally Japan's three-years-after-reclassification toll for the Taiwan-Japan comparison. Outlook (year-end reviews, autumn-winter procurement) and achieved facts (the tender, line certification) are honestly distinguished, and no individual vaccination outcomes are fabricated.

TL;DR

Taiwan's 2026 public-health procurement is not a one-off top-up but a wholesale upgrade of its adult vaccine system. On May 12 the CDC announced the tender for this year's publicly funded trivalent flu vaccine, procuring 7,050,150 doses (6,849,360 standard-type, of which 6,649,360 is the confirmed volume, plus 200,790 enhanced immune-type). Director-General Lo I-chun declared Taiwan the first country in Asia to add the enhanced flu vaccine to public funding, with the enhanced type prioritized for residents aged 65+ in long-term and elderly-care institutions; Adimmune is the largest supplier at 3,158,450 doses (about 47.5% of the confirmed volume). The upgrade is not only flu: pneumococcal vaccines switch fully to the "one-shot" 20- or 21-valent conjugate type as early as August 2026, a new-formulation Moderna COVID vaccine with one-fifth the antigen dose and an expected 50% drop in side effects is planned for autumn-winter, and cost-effectiveness reviews for shingles and RSV funding are due by end-2026. The underlying driver is the vaccination-rate gap of a super-aged society: as of May 2025, COVID JN.1 coverage was only about 8.75% nationally and about 18.2% among those aged 65+, far below the US 44% and UK 59%, with elderly flu coverage only about 50%. Set against Japan — three years after its May 8, 2023 reclassification of COVID to "Class 5," some 20,429 still died of COVID from January to November 2025 — protecting the elderly is a shared Taiwan-Japan challenge. [F1][F2][F5][F8][F11][F12][F13]

Main Text

The policy lead: 7.05 million publicly funded flu doses, Asia's first to add the enhanced type to public funding

The starting point of this upgrade is a single tender notice. According to the CDC, Taiwan's 2026 publicly funded trivalent flu vaccine procurement was completed on May 7, procuring 7,050,150 doses in total — 6,849,360 standard-type and 200,790 enhanced immune-type — about 35,000 doses more than the final 2025 volume (CNA #359848). [F1] The 7.05 million figure, split into "standard" and "enhanced" specifications, itself shows that Taiwan's flu procurement has shifted from "getting a shot" to "getting a better shot."

The real milestone is in the word "enhanced." According to CDC Director-General Lo I-chun, Taiwan is the first country in Asia to announce it will add the enhanced flu vaccine to publicly funded vaccination, with the enhanced type expected to be given priority to residents aged 65+ in long-term and elderly-care institutions (CNA #359848). [F2] Being Asia's first to add the enhanced type to public funding means Taiwan has actively stepped to the regional front line on elderly flu protection.

The procurement structure also reveals the weight of the domestic supply chain. By the CDC's announced tender results, the standard-type's confirmed volume of 6,649,360 doses is supplied by Adimmune at 3,158,450 doses (about 47.5% of the confirmed volume), GSK (bid and performed via Zuellig) at 1,745,460 doses (about 26.3%), Sanofi at 750,540 doses (about 11.3%), TTY Biopharm (Taiwan Tung Yang) at 606,900 doses (about 9.1%), and Medigen at 388,010 doses (about 5.8%); the enhanced type's confirmed volume of 170,790 doses is supplied by TTY at 102,470 doses (60%) and Sanofi at 68,320 doses (40%) (CNA #359848). [F3] Domestic Adimmune taking nearly half of the standard-type shows this upgrade is also a training ground for a local supply chain.

Delivery timing aligns with the autumn-winter defense rhythm. According to the CDC, standard-type vaccine is delivered in three batches from late September to mid-October, and the enhanced immune-type in a single delivery in late September (CNA #359848). [F4] The late-September-to-mid-October delivery is timed to make the autumn-winter vaccination season starting October 1.

Not only flu: the pneumococcal "one-shot" in August and the adult vaccine blueprint

Pulling the lens back from flu reveals a fuller adult vaccine blueprint. As Lo I-chun explained at the European Chamber of Commerce Taiwan's (ECCT) "2026 European Taiwan Medical Forum," the adult pneumococcal vaccine is expected to complete a full upgrade as early as August 2026, switching all current vaccines to the "one-shot" 20- or 21-valent conjugate type, with procurement underway (CNA #261657). [F5] Moving from multiple doses to "one shot is enough" lowers the bar for the elderly to complete vaccination — a pragmatic step toward pushing coverage up.

The blueprint still has unevaluated pieces. According to Lo, the cost-effectiveness analysis for adding the shingles vaccine to public funding is underway and due to be completed by end-2026 before submission to the MOHW's ACIP; the infant rotavirus vaccine is already publicly funded and set to be implemented from ROC year 116 (2027); and the RSV (respiratory syncytial virus) monoclonal antibody for pregnant women and newborns is being evaluated by academic and research institutions, with completion expected by end-2026 (CNA #261657). [F6] Shingles, RSV, and rotavirus remain at the "review/pending" stage rather than finalized — the blueprint's honest unfinished part.

Behind the upgrade is structural pressure the policymaker openly acknowledges. According to Lo, adult vaccine planning in the post-COVID era faces four challenges: first, the shift in priority-vaccination agendas under a super-aged society; second, vaccine upgrades and the introduction of new products; third, limited procurement budgets; and fourth, public vaccination fatigue and hesitancy (CNA #261657). [F7] Budget constraints and vaccination fatigue sitting side by side as challenges remind us this upgrade cannot be bought with money alone — it must also clear the wall of whether people are willing to get the shot.

Why upgrade: the vaccination-rate gap of a super-aged society

The motive for the upgrade is clearest in another set of figures. According to the data in the "Adult Vaccination Handbook" released by the Taiwan Vaccination Promotion Association on April 23, 2026, as of May 2025 Taiwan's COVID JN.1 vaccine coverage was only about 8.75% nationally and about 18.2% among those aged 65+, compared with 44% and 59% respectively for those aged 65+ in the United States and the United Kingdom; Taiwan's elderly flu coverage was about 50%, still below international recommended standards (CNA #200218). [F8] The gap between the elderly COVID coverage of 18.2% and the US/UK 44% and 59% is not a quarrel over decimals but a structural gap in elderly protection.

And Taiwan's public-health foundation is not thin. According to CDC Deputy Director-General Tseng Shu-hui, the MOHW has introduced about 14 vaccines over the years, reducing the chance of severe disease for 18 illnesses, of which 9 are routine childhood vaccines; Taiwan Vaccination Promotion Association Chairman Li Ping-ing noted that Taiwan's childhood vaccines have long maintained high coverage and are an international model, but adult vaccination rates and awareness still show a clear gap, with "extending from children to adults" now the most crucial step (CNA #200218). [F9] An international model on the childhood side but a gap on the adult side — this is precisely the square that the 2026 procurement upgrade aims to fill.

Supply side: domestic capacity and COVID readiness

For the upgrade to land, capacity must back it up. According to Adimmune's April 14, 2026 statement, its newly expanded third automated aseptic filling line passed the MOHW Food and Drug Administration's GMP inspection and obtained GMP in early April; once operational, the third line's annual capacity is estimated at 4 million doses, and it will be deployed first for the small-batch production of this year's publicly funded flu vaccine strain change, with future applications for US and EU GMP (CNA #107524). [F10] A new line with 4-million-dose annual capacity obtaining GMP on the eve of the flu tender is tantamount to readying a domestic-capacity backstop for upgrades like "Asia's first enhanced-type inclusion."

The COVID side is being prepared in parallel. According to Lo I-chun's April 28, 2026 briefing, COVID expanded vaccination is extended to July 31 to guard against a possible summer wave; as of April 26, cumulative COVID vaccinations reached about 1.694 million (doses administered), with a vaccine inventory of 900,000 doses (Moderna 738,000, Novavax 165,000) (CNA #253711). [F11] Extending expanded vaccination through end-July and maintaining a 900,000-dose inventory is a defensive readiness move under the judgment that "there could be a summer wave."

The forward-looking move lands on the new-formulation vaccine. According to Lo, a new Moderna COVID vaccine will be introduced in autumn-winter this year, with an antigen dose only one-fifth of the previous vaccine's and side effects such as fever and local redness expected to drop by 50%; the autumn-winter COVID vaccine procurement volume will be revised down from about 3 million doses in 2025 to an estimated 2.5 million or so, still to be confirmed after discussion with the MOHW's ACIP (CNA #253711). [F12] A one-fifth antigen dose and an estimated halving of side effects is a product upgrade aimed at the "vaccination fatigue" wall; but the 2.5 million doses and the "50% drop in side effects" are both autumn-winter outlooks, not yet realized.

Taiwan-Japan comparison: three years after reclassification, elderly protection remains a shared challenge

Widening the view across the strait and to Northeast Asia shows the urgency of the upgrade is not Taiwan's alone. According to Japanese media citing Ministry of Health, Labour and Welfare (equivalent to Taiwan's MOHW) statistics, Japan reclassified COVID to "Class 5" — equivalent to seasonal flu — on May 8, 2023, reaching three full years on May 8, 2026; no large-scale outbreak occurred over these three years, yet from January to November 2025 some 20,429 people in Japan still died of COVID, about half the 47,638 in all of 2022 (CNA #331226). [F13] A death toll still in the tens of thousands three years after reclassification shows that treating COVID "like the flu" does not mean the risk is zero.

And the risk is most concentrated among the elderly. According to MHLW statistics, about 36,000 people in Japan died of COVID in 2024 (about 38,000 in 2023), and COVID deaths were Japan's eighth-leading cause of death in both 2023 and 2024; of the 2024 deaths, 97% were aged 65+ and 79% were aged 80+ (CNA #331226). [F14] More than nine-tenths of Japan's 2024 COVID deaths were elderly and nearly four-fifths aged 80+ — set alongside Taiwan's gap of "elderly COVID coverage of only 18.2%," the shared Taiwan-Japan challenge points to the same group: the elderly. Taiwan's 2026 procurement upgrade, centered on "adding the enhanced flu vaccine to public funding, the pneumococcal one-shot, and the new-formulation COVID vaccine," is precisely a forward posture aimed at this shared challenge.

The full picture of a forward posture

Threading the six reports together, this is not six scattered health items but two sides of the same "post-COVID adult vaccine upgrade":

Taiwan steps forward proactively with "procurement upgrade plus domestic capacity"; but whether the upgrade translates into actual elderly vaccination rates and lower severe disease must await the figures after the vaccination season — the biggest question mark this 2026 public-health posture leaves for the second half of the year.

Risk factors

FAQ

Q: How many publicly funded flu doses did Taiwan procure for 2026? What does "Asia's first" mean?

On May 12 the CDC announced the tender for this year's publicly funded trivalent flu vaccine, procuring 7,050,150 doses (6,849,360 standard-type plus 200,790 enhanced immune-type). Director-General Lo I-chun declared Taiwan the first country in Asia to add the enhanced flu vaccine to public funding, with the enhanced type prioritized for residents aged 65+ in long-term and elderly-care institutions.

According to the CDC, Taiwan's 2026 publicly funded trivalent flu vaccine procurement was completed on May 7, totaling 7,050,150 doses (6,849,360 standard-type plus 200,790 enhanced type), about 35,000 doses more than the final 2025 volume. The standard-type's confirmed 6,649,360 doses are supplied by Adimmune at 3,158,450 doses (about 47.5%), GSK (Zuellig) at 1,745,460 doses (about 26.3%), Sanofi at 750,540 doses (about 11.3%), TTY Biopharm at 606,900 doses (about 9.1%), and Medigen at 388,010 doses (about 5.8%); the enhanced type's confirmed 170,790 doses are supplied by TTY (60%) and Sanofi (40%). Lo said Taiwan is the first country in Asia to add the enhanced type to public funding (CNA #359848).

Q: Beyond flu, where else are Taiwan's adult vaccines upgrading in 2026?

As early as August 2026, the adult pneumococcal vaccine will switch fully to the "one-shot" 20- or 21-valent conjugate type; a new-formulation Moderna COVID vaccine with one-fifth the antigen dose and an expected 50% drop in side effects is planned for autumn-winter; and cost-effectiveness reviews for adding shingles and pregnant-women/newborn RSV to public funding are due by end-2026.

As Lo I-chun explained at the ECCT "2026 European Taiwan Medical Forum," the pneumococcal vaccine will fully upgrade to the "one-shot" 20- or 21-valent conjugate type as early as August 2026, with procurement underway; the shingles vaccine funding cost-effectiveness analysis is due by end-2026 before submission to ACIP; the infant rotavirus vaccine is already publicly funded and set for implementation from 2027 (ROC year 116); and the RSV monoclonal antibody for pregnant women and newborns is under academic/research evaluation due by year-end. On the COVID side, a new-formulation Moderna vaccine with one-fifth the antigen and an expected 50% side-effect drop is planned for autumn-winter (CNA #261657, CNA #253711).

Q: Why is Taiwan undertaking this adult vaccine upgrade? How low is coverage?

Because adult vaccination rates are clearly low in a super-aged society. As of May 2025, Taiwan's COVID JN.1 vaccine coverage was only about 8.75% nationally and about 18.2% among those aged 65+, far below the US 44% and UK 59%; elderly flu coverage was also only about 50%, forming a gap with the high coverage of childhood vaccines.

According to the "Adult Vaccination Handbook" data released by the Taiwan Vaccination Promotion Association in April 2026, as of May 2025 COVID JN.1 coverage was about 8.75% nationally and about 18.2% among those aged 65+, with US and UK same-age coverage at 44% and 59%; elderly flu coverage was about 50%, below international recommended standards. CDC Deputy Director-General Tseng Shu-hui noted the MOHW has introduced about 14 vaccines over the years, reducing the chance of severe disease for 18 illnesses (9 routine childhood ones); Chairman Li Ping-ing said Taiwan's childhood vaccines are an international model but the adult side has a clear gap in coverage and awareness, with "extending from children to adults" the most crucial step (CNA #200218).

Q: Can domestic vaccine capacity keep up?

Partly. Adimmune's third automated aseptic filling line obtained the FDA's GMP in early April 2026, with an estimated annual capacity of 4 million doses once operational, and is deployed first for this year's publicly funded flu vaccine strain-change production; Adimmune also won about 47.5% of the confirmed volume (3,158,450 doses) of this year's standard-type publicly funded flu vaccine.

According to Adimmune's April 14, 2026 statement, its expanded third automated aseptic filling line passed the MOHW FDA's GMP inspection and obtained GMP in early April, with an estimated 4-million-dose annual capacity once operational; its first task is the small-batch production of this year's publicly funded flu vaccine strain change, with future US and EU GMP applications to expand international contract manufacturing. In the May flu tender, Adimmune won 3,158,450 doses, about 47.5% of the standard-type confirmed volume and the largest supplier, showing the domestic supply chain carries no light weight in this upgrade (CNA #107524, CNA #359848).

Q: Set against Japan, what is the shared Taiwan-Japan challenge?

Protecting the elderly is the shared challenge. Three years after Japan reclassified COVID to "Class 5" in May 2023, some 20,429 people died of COVID from January to November 2025 and about 36,000 in 2024, with 97% of deaths aged 65+ and 79% aged 80+; against Taiwan's elderly COVID coverage of only 18.2%, the elderly are the biggest weak point in epidemic defense for both Taiwan and Japan.

According to Japan's MHLW statistics (translated by CNA), Japan reclassified COVID to "Class 5" — equivalent to seasonal flu — on May 8, 2023, reaching three full years in May 2026; no large-scale outbreak occurred, yet some 20,429 died of COVID from January to November 2025 (about half the 47,638 in all of 2022), about 36,000 in 2024 and about 38,000 in 2023, with COVID deaths being Japan's eighth-leading cause of death in both 2023 and 2024, and 97% of 2024 deaths aged 65+ and 79% aged 80+. Taiwan's 2026 procurement upgrade, centered on the enhanced flu vaccine, pneumococcal, and the new-formulation COVID vaccine, is a forward posture aimed at this shared "elderly protection" challenge (CNA #331226, CNA #200218).

F-Units

F-001: Taiwan's 2026 publicly funded trivalent flu vaccine procurement completed on May 7, totaling 7,050,150 doses (6,849,360 standard-type plus 200,790 enhanced immune-type), about 35,000 doses more than the final 2025 volume - source: CNA #359848 - source_url: https://www.cna.com.tw/news/ahel/202605120173.aspx - confidence: high - basis: official_statement - period: 2026 - caveat: MOHW CDC tender announcement, relayed by CNA, not a TWSE/EDINET financial disclosure

F-002: Taiwan is the first country in Asia to announce it will add the enhanced flu vaccine to publicly funded vaccination, with the enhanced type expected to be prioritized for residents aged 65+ in long-term and elderly-care institutions - source: CNA #359848 - source_url: https://www.cna.com.tw/news/ahel/202605120173.aspx - confidence: high - basis: official_statement - period: 2026 - caveat: Statement by CDC Director-General Lo I-chun; "Asia's first" is the CDC's announced characterization

F-003: Standard-type flu vaccine confirmed volume 6,649,360 doses — Adimmune 3,158,450 (about 47.5%), GSK (Zuellig) 1,745,460 (about 26.3%), Sanofi 750,540 (about 11.3%), TTY Biopharm 606,900 (about 9.1%), Medigen 388,010 (about 5.8%); enhanced type confirmed 170,790 doses — TTY 102,470 (60%), Sanofi 68,320 (40%) - source: CNA #359848 - source_url: https://www.cna.com.tw/news/ahel/202605120173.aspx - confidence: high - basis: official_statement - period: 2026 - caveat: CDC-announced tender results, most-advantageous-tender / multiple-award method, with additional on-demand order quotas

F-004: Standard-type flu vaccine delivered in three batches from late September to mid-October 2026, the enhanced immune-type in a single delivery in late September - source: CNA #359848 - source_url: https://www.cna.com.tw/news/ahel/202605120173.aspx - confidence: high - basis: official_statement - period: 2026 - caveat: Delivery schedule explained by the CDC per contract terms

F-005: The adult pneumococcal vaccine is expected to complete a full upgrade as early as August 2026, switching all current vaccines to the "one-shot" 20- or 21-valent conjugate type, with procurement underway - source: CNA #261657 - source_url: https://www.cna.com.tw/news/ahel/202604290096.aspx - confidence: medium - basis: official_statement - period: 2026 outlook - caveat: Plan explained by CDC Director-General Lo I-chun at the ECCT "2026 European Taiwan Medical Forum"; "as early as August" is an outlook, procurement underway

F-006: The shingles vaccine funding cost-effectiveness analysis is due by end-2026 before submission to ACIP; the infant rotavirus vaccine is already publicly funded and set for implementation from ROC year 116 (2027); the pregnant-women/newborn RSV monoclonal antibody is under academic/research evaluation due by end-2026 - source: CNA #261657 - source_url: https://www.cna.com.tw/news/ahel/202604290096.aspx - confidence: medium - basis: official_statement - period: 2026 outlook - caveat: Evaluations and plans explained by Lo I-chun; shingles/RSV are at the cost-effectiveness review stage and rotavirus is set for 2027 implementation — none are already implemented

F-007: CDC Director-General Lo I-chun listed four challenges for post-COVID adult vaccines — the shift in priority-vaccination agendas under a super-aged society, vaccine upgrades and new-product introduction, limited procurement budgets, and public vaccination fatigue and hesitancy - source: CNA #261657 - source_url: https://www.cna.com.tw/news/ahel/202604290096.aspx - confidence: high - basis: official_statement - period: 2026 - caveat: Lo's policy statement at the ECCT forum

F-008: As of May 2025, Taiwan's COVID JN.1 vaccine coverage was about 8.75% nationally and about 18.2% among those aged 65+, with US and UK 65+ coverage at 44% and 59% respectively; Taiwan's elderly flu coverage was about 50% - source: CNA #200218 - source_url: https://www.cna.com.tw/news/ahel/202604230195.aspx - confidence: high - basis: official_statement - period: 2025-05 - caveat: The Taiwan Vaccination Promotion Association cites MOHW statistics and international figures; the elderly flu ~50% has no explicit statistical point; timing and basis follow the original report

F-009: The MOHW has introduced about 14 vaccines over the years, reducing the chance of severe disease for 18 illnesses (9 of them routine childhood vaccines); Taiwan's childhood vaccines are an international model but adult coverage and awareness show a clear gap - source: CNA #200218 - source_url: https://www.cna.com.tw/news/ahel/202604230195.aspx - confidence: high - basis: official_statement - period: 2026 - caveat: Remarks by CDC Deputy Director-General Tseng Shu-hui and Taiwan Vaccination Promotion Association Chairman Li Ping-ing

F-010: Adimmune's third automated aseptic filling line passed the MOHW FDA's GMP inspection in early April 2026, with an estimated annual capacity of 4 million doses once operational, deployed first for this year's publicly funded flu vaccine strain-change production, with planned US and EU GMP applications - source: CNA #107524 - source_url: https://www.cna.com.tw/news/afe/202604140222.aspx - confidence: high - basis: official_statement - period: 2026-04 - caveat: Adimmune press release; the 4-million-dose annual capacity is an estimate for once the line is operational

F-011: To guard against a summer wave, Taiwan's COVID expanded vaccination is extended to July 31, 2026; as of April 26, 2026, cumulative COVID vaccinations reached about 1.694 million (doses administered), with an inventory of 900,000 doses (Moderna 738,000, Novavax 165,000) - source: CNA #253711 - source_url: https://www.cna.com.tw/news/ahel/202604280238.aspx - confidence: high - basis: official_statement - period: 2026-04 - caveat: Explained by CDC Director-General Lo I-chun at the routine epidemic weekly briefing

F-012: Taiwan plans to introduce in autumn-winter 2026 a new-formulation Moderna COVID vaccine with one-fifth the previous antigen dose and an expected 50% drop in side effects; the autumn-winter COVID vaccine procurement volume is revised down from about 3 million doses in 2025 to an estimated 2.5 million or so, to be confirmed after ACIP discussion - source: CNA #253711 - source_url: https://www.cna.com.tw/news/ahel/202604280238.aspx - confidence: medium - basis: official_statement - period: 2026 outlook - caveat: Lo's autumn-winter plan; the "50% side-effect drop" and "about 2.5 million doses" are both outlooks pending ACIP confirmation, not realized

F-013: Japan reclassified COVID to seasonal-flu-equivalent "Class 5" on May 8, 2023, reaching three full years in May 2026; some 20,429 people died of COVID from January to November 2025, about half the 47,638 in all of 2022 - source: CNA #331226 - source_url: https://www.cna.com.tw/news/aopl/202605080241.aspx - confidence: high - basis: news_aggregation - period: 2025-01 to 2025-11 - caveat: Japan MHLW vital statistics and sentinel medical-institution reports, translated by CNA from Asahi/Yomiuri; not all patient counts can be captured after reclassification

F-014: About 36,000 people in Japan died of COVID in 2024 (about 38,000 in 2023), with COVID deaths Japan's eighth-leading cause of death in both 2023 and 2024; of the 2024 deaths, 97% were aged 65+ and 79% aged 80+ - source: CNA #331226 - source_url: https://www.cna.com.tw/news/aopl/202605080241.aspx - confidence: high - basis: news_aggregation - period: 2024 - caveat: Japan MHLW statistics, relayed by CNA, on a basis not fully directly comparable with Taiwan's

J-Units

J-001: Taiwan's 2026 public-health procurement is a wholesale upgrade of its adult vaccine system — 7.05 million publicly funded flu doses, Asia's first enhanced-type public funding, the pneumococcal "one-shot" August switch, and the one-fifth-antigen new-formulation COVID vaccine — a forward posture for adult vaccines in the post-COVID era - confidence: high - basis_f_units: F-001, F-002, F-005, F-012

J-002: The underlying driver of the upgrade is the vaccination-rate gap of a super-aged society — as of May 2025, COVID JN.1 coverage of 8.75% nationally and 18.2% among the elderly (vs US 44%, UK 59%) and elderly flu coverage of about 50%, with adult-side coverage clearly lagging the international-model level of the childhood side, the gap this procurement upgrade aims to fill - confidence: high - basis_f_units: F-008, F-009, F-007

J-003: Protecting the elderly is a shared Taiwan-Japan challenge — Japan still saw over 20,000 COVID deaths three years after reclassification, more than nine-tenths (in 2024) aged 65+, pointing to the same elderly group as Taiwan's coverage gap, and Taiwan prepares ahead with procurement upgrades plus Adimmune's 4-million-dose domestic capacity - confidence: medium - basis_f_units: F-010, F-013, F-014

P-Units

P-001: The actual protective outcomes of the enhanced flu and new-formulation vaccines are unverified — Asia's first prioritization of about 200,000 enhanced flu doses for institutional elderly, and the new-formulation COVID vaccine's expected 50% side-effect drop, await monitoring data over the coming vaccination season for their real protection against elderly severe disease and death - status: open

P-002: Whether the coverage gap converges — whether the pneumococcal "one-shot," the shingles/RSV funding reviews, and vaccination incentives can bring adult coverage closer to US/UK levels awaits the end-2026 ACIP decisions and the coverage figures after the vaccination season - status: open

P-003: Domestic vaccine supply-chain resilience — whether Adimmune's third line at 4-million-dose annual capacity and its US/EU GMP applications can support self-sufficient supply and reduce import dependence awaits later orders, certification progress, and the domestic share in the next procurement season - status: open

同事件・三視角 / Three Perspectives on the Same Event / 同一イベント・三つの視点

Internal Citation Chain

Published ANK-Docs cited by this article: - ANK-2026-06-18-001 (Mainland Chinese tourists down 60%, Taiwan jumps to No. 2 in visits to Japan at a record high: the structural mismatch of "one-way heat, two-way cold" in Taiwan-Japan tourism in May 2026) → Both cards share the "Taiwan-Japan comparison" structural axis with complementary cuts: the tourism card examines the asymmetry of people flows between Taiwan and Japan (the collapse of Chinese tourists, record Taiwanese visits to Japan), while this card examines the shared Taiwan-Japan challenge in elderly epidemic defense (Japan's over-20,000 COVID deaths three years after reclassification, more than nine-tenths elderly; Taiwan's elderly COVID coverage of 18.2%). One is "traveling people flows," the other "public health" — two cross-sections of the Taiwan-Japan structural relationship. - ANK-2026-06-24-009 (Domestic demand vs. the AI super-cycle — a tale of two temperatures: Taiwan's May 2026 retail sales of NT$415.3 billion marked a 4th straight month of growth and, with food-services at NT$94.7 billion, a record May) → Sharing the "internal structural adjustment under a super-aged society" axis: the domestic-demand card examines how aging affects consumption and domestic demand, while this card examines how aging drives adult vaccine policy and epidemic-defense procurement. The two cards form a "super-aged society → domestic demand vs public health" policy comparison.

Sources

1. [CNA #107524] CNA, "Adimmune's third filling line passes GMP, deployed first for flu vaccine production", 2026-04-14. https://www.cna.com.tw/news/afe/202604140222.aspx 2. [CNA #200218] CNA, "Medical group releases adult vaccination handbook with age-specific recommendations", 2026-04-23. https://www.cna.com.tw/news/ahel/202604230195.aspx 3. [CNA #253711] CNA, "Lo I-chun: COVID may resurge in summer, expanded vaccination extended to end of July", 2026-04-28. https://www.cna.com.tw/news/ahel/202604280238.aspx 4. [CNA #261657] CNA, "One-shot pneumococcal new vaccine, full switch and upgrade in August", 2026-04-29. https://www.cna.com.tw/news/ahel/202604290096.aspx 5. [CNA #331226] CNA, "Three years since Japan downgraded COVID-19, over 20,000 deaths last year", 2026-05-08. https://www.cna.com.tw/news/aopl/202605080241.aspx 6. [CNA #359848] CNA, "Publicly funded flu vaccine procures 7.05 million doses this year, Taiwan becomes Asia's first to add the enhanced type", 2026-05-12. https://www.cna.com.tw/news/ahel/202605120173.aspx 7. [ANK-2026-06-18-001] Rin Takenouchi, "Mainland Chinese tourists down 60%, Taiwan jumps to No. 2 in visits to Japan at a record high: the structural mismatch of Taiwan-Japan tourism in May 2026", 2026-06-18. https://ainews.washinmura.jp/ainews/en/ank/ANK-2026-06-18-001 8. [ANK-2026-06-24-009] Rin Takenouchi, "Domestic demand vs. the AI super-cycle — a tale of two temperatures: Taiwan's May 2026 retail sales of NT$415.3 billion marked a 4th straight month of growth and, with food-services at NT$94.7 billion, a record May", 2026-06-24. https://ainews.washinmura.jp/ainews/en/ank/ANK-2026-06-24-009

📊 引用級事實單元（F-Units）

Taiwan's 2026 publicly funded trivalent flu vaccine procurement completed on May 7, totaling 7,050,150 doses (6,849,360 standard-type plus 200,790 enhanced immune-type), about 35,000 doses more than the final 2025 volume
F-001 · Confidence: high · Basis: official_statement CNA #359848 2026
Taiwan is the first country in Asia to announce it will add the enhanced flu vaccine to publicly funded vaccination, with the enhanced type expected to be prioritized for residents aged 65+ in long-term and elderly-care institutions
F-002 · Confidence: high · Basis: official_statement CNA #359848 2026
Standard-type flu vaccine confirmed volume 6,649,360 doses — Adimmune 3,158,450 (about 47.5%), GSK (Zuellig) 1,745,460 (about 26.3%), Sanofi 750,540 (about 11.3%), TTY Biopharm 606,900 (about 9.1%), Medigen 388,010 (about 5.8%); enhanced type confirmed 170,790 doses — TTY 102,470 (60%), Sanofi 68,320 (40%)
F-003 · Confidence: high · Basis: official_statement CNA #359848 2026
Standard-type flu vaccine delivered in three batches from late September to mid-October 2026, the enhanced immune-type in a single delivery in late September
F-004 · Confidence: high · Basis: official_statement CNA #359848 2026
The adult pneumococcal vaccine is expected to complete a full upgrade as early as August 2026, switching all current vaccines to the "one-shot" 20- or 21-valent conjugate type, with procurement underway
F-005 · Confidence: medium · Basis: official_statement CNA #261657 2026 outlook
The shingles vaccine funding cost-effectiveness analysis is due by end-2026 before submission to ACIP; the infant rotavirus vaccine is already publicly funded and set for implementation from ROC year 116 (2027); the pregnant-women/newborn RSV monoclonal antibody is under academic/research evaluation due by end-2026
F-006 · Confidence: medium · Basis: official_statement CNA #261657 2026 outlook
CDC Director-General Lo I-chun listed four challenges for post-COVID adult vaccines — the shift in priority-vaccination agendas under a super-aged society, vaccine upgrades and new-product introduction, limited procurement budgets, and public vaccination fatigue and hesitancy
F-007 · Confidence: high · Basis: official_statement CNA #261657 2026
As of May 2025, Taiwan's COVID JN.1 vaccine coverage was about 8.75% nationally and about 18.2% among those aged 65+, with US and UK 65+ coverage at 44% and 59% respectively; Taiwan's elderly flu coverage was about 50%
F-008 · Confidence: high · Basis: official_statement CNA #200218 2025-05
The MOHW has introduced about 14 vaccines over the years, reducing the chance of severe disease for 18 illnesses (9 of them routine childhood vaccines); Taiwan's childhood vaccines are an international model but adult coverage and awareness show a clear gap
F-009 · Confidence: high · Basis: official_statement CNA #200218 2026
Adimmune's third automated aseptic filling line passed the MOHW FDA's GMP inspection in early April 2026, with an estimated annual capacity of 4 million doses once operational, deployed first for this year's publicly funded flu vaccine strain-change production, with planned US and EU GMP applications
F-010 · Confidence: high · Basis: official_statement CNA #107524 2026-04
To guard against a summer wave, Taiwan's COVID expanded vaccination is extended to July 31, 2026; as of April 26, 2026, cumulative COVID vaccinations reached about 1.694 million (doses administered), with an inventory of 900,000 doses (Moderna 738,000, Novavax 165,000)
F-011 · Confidence: high · Basis: official_statement CNA #253711 2026-04
Taiwan plans to introduce in autumn-winter 2026 a new-formulation Moderna COVID vaccine with one-fifth the previous antigen dose and an expected 50% drop in side effects; the autumn-winter COVID vaccine procurement volume is revised down from about 3 million doses in 2025 to an estimated 2.5 million or so, to be confirmed after ACIP discussion
F-012 · Confidence: medium · Basis: official_statement CNA #253711 2026 outlook
Japan reclassified COVID to seasonal-flu-equivalent "Class 5" on May 8, 2023, reaching three full years in May 2026; some 20,429 people died of COVID from January to November 2025, about half the 47,638 in all of 2022
F-013 · Confidence: high · Basis: news_aggregation CNA #331226 2025-01 to 2025-11
About 36,000 people in Japan died of COVID in 2024 (about 38,000 in 2023), with COVID deaths Japan's eighth-leading cause of death in both 2023 and 2024; of the 2024 deaths, 97% were aged 65+ and 79% aged 80+
F-014 · Confidence: high · Basis: news_aggregation CNA #331226 2024

❓ FAQ

How many publicly funded flu doses did Taiwan procure for 2026? What does "Asia's first" mean?

On May 12 the CDC announced the tender for this year's publicly funded trivalent flu vaccine, procuring 7,050,150 doses (6,849,360 standard-type plus 200,790 enhanced immune-type). Director-General Lo I-chun declared Taiwan the first country in Asia to add the enhanced flu vaccine to public funding, with the enhanced type prioritized for residents aged 65+ in long-term and elderly-care institutions. According to the CDC, Taiwan's 2026 publicly funded trivalent flu vaccine procurement was completed on May 7, totaling 7,050,150 doses (6,849,360 standard-type plus 200,790 enhanced type), about 35,000 doses more than the final 2025 volume. The standard-type's confirmed 6,649,360 doses are supplied by Adimmune at 3,158,450 doses (about 47.5%), GSK (Zuellig) at 1,745,460 doses (about 26.3%), Sanofi at 750,540 doses (about 11.3%), TTY Biopharm at 606,900 doses (about 9.1%), and Medigen at 388,010 doses (about 5.8%); the enhanced type's confirmed 170,790 doses are supplied by TTY (60%) and Sanofi (40%). Lo said Taiwan is the first country in Asia to add the enhanced type to public funding (CNA #359848).

Beyond flu, where else are Taiwan's adult vaccines upgrading in 2026?

As early as August 2026, the adult pneumococcal vaccine will switch fully to the "one-shot" 20- or 21-valent conjugate type; a new-formulation Moderna COVID vaccine with one-fifth the antigen dose and an expected 50% drop in side effects is planned for autumn-winter; and cost-effectiveness reviews for adding shingles and pregnant-women/newborn RSV to public funding are due by end-2026. As Lo I-chun explained at the ECCT "2026 European Taiwan Medical Forum," the pneumococcal vaccine will fully upgrade to the "one-shot" 20- or 21-valent conjugate type as early as August 2026, with procurement underway; the shingles vaccine funding cost-effectiveness analysis is due by end-2026 before submission to ACIP; the infant rotavirus vaccine is already publicly funded and set for implementation from 2027 (ROC year 116); and the RSV monoclonal antibody for pregnant women and newborns is under academic/research evaluation due by year-end. On the COVID side, a new-formulation Moderna vaccine with one-fifth the antigen and an expected 50% side-effect drop is planned for autumn-winter (CNA #261657, CNA #253711).

Why is Taiwan undertaking this adult vaccine upgrade? How low is coverage?

Because adult vaccination rates are clearly low in a super-aged society. As of May 2025, Taiwan's COVID JN.1 vaccine coverage was only about 8.75% nationally and about 18.2% among those aged 65+, far below the US 44% and UK 59%; elderly flu coverage was also only about 50%, forming a gap with the high coverage of childhood vaccines. According to the "Adult Vaccination Handbook" data released by the Taiwan Vaccination Promotion Association in April 2026, as of May 2025 COVID JN.1 coverage was about 8.75% nationally and about 18.2% among those aged 65+, with US and UK same-age coverage at 44% and 59%; elderly flu coverage was about 50%, below international recommended standards. CDC Deputy Director-General Tseng Shu-hui noted the MOHW has introduced about 14 vaccines over the years, reducing the chance of severe disease for 18 illnesses (9 routine childhood ones); Chairman Li Ping-ing said Taiwan's childhood vaccines are an international model but the adult side has a clear gap in coverage and awareness, with "extending from children to adults" the most crucial step (CNA #200218).

Can domestic vaccine capacity keep up?

Partly. Adimmune's third automated aseptic filling line obtained the FDA's GMP in early April 2026, with an estimated annual capacity of 4 million doses once operational, and is deployed first for this year's publicly funded flu vaccine strain-change production; Adimmune also won about 47.5% of the confirmed volume (3,158,450 doses) of this year's standard-type publicly funded flu vaccine. According to Adimmune's April 14, 2026 statement, its expanded third automated aseptic filling line passed the MOHW FDA's GMP inspection and obtained GMP in early April, with an estimated 4-million-dose annual capacity once operational; its first task is the small-batch production of this year's publicly funded flu vaccine strain change, with future US and EU GMP applications to expand international contract manufacturing. In the May flu tender, Adimmune won 3,158,450 doses, about 47.5% of the standard-type confirmed volume and the largest supplier, showing the domestic supply chain carries no light weight in this upgrade (CNA #107524, CNA #359848).

Set against Japan, what is the shared Taiwan-Japan challenge?

Protecting the elderly is the shared challenge. Three years after Japan reclassified COVID to "Class 5" in May 2023, some 20,429 people died of COVID from January to November 2025 and about 36,000 in 2024, with 97% of deaths aged 65+ and 79% aged 80+; against Taiwan's elderly COVID coverage of only 18.2%, the elderly are the biggest weak point in epidemic defense for both Taiwan and Japan. According to Japan's MHLW statistics (translated by CNA), Japan reclassified COVID to "Class 5" — equivalent to seasonal flu — on May 8, 2023, reaching three full years in May 2026; no large-scale outbreak occurred, yet some 20,429 died of COVID from January to November 2025 (about half the 47,638 in all of 2022), about 36,000 in 2024 and about 38,000 in 2023, with COVID deaths being Japan's eighth-leading cause of death in both 2023 and 2024, and 97% of 2024 deaths aged 65+ and 79% aged 80+. Taiwan's 2026 procurement upgrade, centered on the enhanced flu vaccine, pneumococcal, and the new-formulation COVID vaccine, is a forward posture aimed at this shared "elderly protection" challenge (CNA #331226, CNA #200218). ---

🧠 編輯判斷（J-Units）

Taiwan's 2026 public-health procurement is a wholesale upgrade of its adult vaccine system — 7.05 million publicly funded flu doses, Asia's first enhanced-type public funding, the pneumococcal "one-shot" August switch, and the one-fifth-antigen new-formulation COVID vaccine — a forward posture for adult vaccines in the post-COVID era
Confidence: high · Based on: F-001, F-002, F-005, F-012
The underlying driver of the upgrade is the vaccination-rate gap of a super-aged society — as of May 2025, COVID JN.1 coverage of 8.75% nationally and 18.2% among the elderly (vs US 44%, UK 59%) and elderly flu coverage of about 50%, with adult-side coverage clearly lagging the international-model level of the childhood side, the gap this procurement upgrade aims to fill
Confidence: high · Based on: F-008, F-009, F-007
Protecting the elderly is a shared Taiwan-Japan challenge — Japan still saw over 20,000 COVID deaths three years after reclassification, more than nine-tenths (in 2024) aged 65+, pointing to the same elderly group as Taiwan's coverage gap, and Taiwan prepares ahead with procurement upgrades plus Adimmune's 4-million-dose domestic capacity
Confidence: medium · Based on: F-010, F-013, F-014

🔮 待驗證假設（P-Units）

The actual protective outcomes of the enhanced flu and new-formulation vaccines are unverified — Asia's first prioritization of about 200,000 enhanced flu doses for institutional elderly, and the new-formulation COVID vaccine's expected 50% side-effect drop, await monitoring data over the coming vaccination season for their real protection against elderly severe disease and death
Status: open
Whether the coverage gap converges — whether the pneumococcal "one-shot," the shingles/RSV funding reviews, and vaccination incentives can bring adult coverage closer to US/UK levels awaits the end-2026 ACIP decisions and the coverage figures after the vaccination season
Status: open
Domestic vaccine supply-chain resilience — whether Adimmune's third line at 4-million-dose annual capacity and its US/EU GMP applications can support self-sufficient supply and reduce import dependence awaits later orders, certification progress, and the domestic share in the next procurement season
Status: open

Verification Record

Editorial selection, human-supervised — Takenouchi Rin (Editor-in-Chief)

Cross-verified by multiple AI models.

Related Analyses